By vgreene, 28 October, 2021 Primary endpoint of time to viral suppression shorter w CQ difference 6 days higher rate of viral clearance w CQ vs controls by day 10 96 vs 91 and by day 14 80 vs 57 duration of fever shorter w CQ no difference in LOS similar rates of ADRs in both groups
By vgreene, 28 October, 2021 Multicenter prospective observational study 197 hospitalized pts mean age 44y 91 moderate dz w confirmed SARS CoV 2 received CQ 500 mg qd or bid for up to 10 days 176 historical controls mean age 46y received other antiviral tx time btwn sx onset and tx s
By vgreene, 28 October, 2021 Study considerations non randomized historical controls treated w various antivirals demographics and tx differed across time and btwn sites incl dosing and timing of tx start mostly moderate dz incomplete clinical and lab data collection
By vgreene, 28 October, 2021 Preliminary Evidence From a Multicenter Prospective Observational Study of the Safety and Efficacy of Chloroquine for the Treatment of COVID 19
